Charlotta Hedner

Medicine & Life Sciences

1. Adenocarcinoma 100%
2. Stomach 72%
3. Neoplasms 34%
4. Survival 32%
5. Biomarkers 29%
6. human ERBB2 protein 27%
7. podocalyxin 24%
8. AT Rich Sequence 23%
9. Stomach Neoplasms 20%
10. Esophageal Neoplasms 18%
11. Chemoradiotherapy 17%
12. B-Lymphocytes 17%
13. Recurrence 16%
14. Metaplasia 16%
15. Plasma Cells 15%
16. Drug Therapy 13%
17. Proteins 13%
18. Junctional Adhesion Molecule A 13%
19. Upper Gastrointestinal Tract 12%
20. Polymeric Immunoglobulin Receptors 12%
21. Neoadjuvant Therapy 11%
22. DNA Mismatch Repair 11%
23. ErbB Receptors 11%
24. Macrophages 10%
25. RNA-Binding Motifs 10%
26. T-Lymphocytes 9%
27. Tumor-Infiltrating Lymphocytes 9%
28. Death Domain Receptors 9%
29. Neoplasm Metastasis 8%
30. RNA-Binding Proteins 8%
31. Ovarian Epithelial Carcinoma 8%
32. Machine Learning 8%
33. Lymphocyte Activation 8%
34. Radiology 7%
35. Pulmonary Embolism 7%
36. Lymph Nodes 7%
37. Cell Count 7%
38. Natural Killer Cells 6%
39. Carrier Proteins 6%
40. Interferons 6%
41. Adenocarcinoma Of Esophagus 6%
42. Immunohistochemistry 6%
43. Referral and Consultation 5%
44. Ligands 5%
45. Nuclear RNA 5%
46. Gene Expression 5%